Nordic Nanovector ASA - Financial calendar

Report this content

Oslo, Norway, 10 March 2020


Financial calendar for Nordic Nanovector ASA



27.03.2020 - Annual Report



27.08.2020 - Half-yearly Report

30.04.2020 - Annual General Meeting


26.05.2020 - Quarterly Report - Q1

19.11.2020 - Quarterly Report - Q3


For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications
Cell: +44 7561 431 762

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.

Further information can be found at


This information is published pursuant to the requirements set out in the Continuing obligations.